Article

Integrative analysis of patient-derived tumoroids and ex vivo organoid modeling of ARID1A loss in bladder cancer reveals therapeutic molecular targets

2024-08-02

Abstract excerpt

Somatic mutations in ARID1A (AT-rich interactive domain-containing protein 1A) are present in approximately 25% of bladder cancers (BC) and are associated with poor prognosis. With a view to discover effective treatment options for ARID1A-deficient BC patients, we set out to identify targetable effectors dysregulated consequent to ARID1A deficiency. Integrative analyses of ARID1A depletion in normal organoids and...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6b302945-902b-55f9-bc08-7238fadf40a4
DOI: 10.1101/2024.07.29.601702

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Integrative analysis of patient-derived tumoroids and ex vivo organoid modeling of ARID1A loss in bladder cancer reveals therapeutic molecular targetsDOI 10.1101/2024.07.29.601702Read

Integrative analysis of patient-derived tumoroids and ex vivo organoid modelling of ARID1A loss in bladder cancer reveals therapeutic molecular targetsSemantic proximity Read

Therapeutic significance of ARID1A mutation in bladder cancer.Semantic proximity Read

Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer.Semantic proximity Read

Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.Semantic proximity Read

ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitorsSemantic proximity Read

ARID1A Alterations Are Associated with FGFR3-Wild Type, Poor-Prognosis, Urothelial Bladder TumorsSemantic proximity Read

ARID1A-mutant and deficient bladder cancer is sensitive to EZH2 pharmacologic inhibitionSemantic proximity Read

ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC.Semantic proximity Read

Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancerSemantic proximity Read

A CRISPR/Cas9-Engineered ARID1A-Deficient Human Gastric Cancer Organoid Model Reveals Essential and Nonessential Modes of Oncogenic Transformation.Semantic proximity Read

Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.Semantic proximity Read

Co-regulator activity of Mediator of DNA Damage Checkpoint 1 (MDC1) is associated with DNA repair dysfunction and PARP inhibitor sensitivity in lobular carcinoma of the breastSemantic proximity Read